13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting AURKA, AURKB and AURKC could enhance the efficacy of T790M-mutant EGFR inhibitors against EGFR-mutant NSCLC. Screening of 94 compounds against cancer pathway...
03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...
17:46 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived metastatic neuroendocrine prostate cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by culturing enzyme-dissociated cells from samples of a patient’s liver, lymph node...
19:02 , May 31, 2018 |  BC Innovations  |  Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
14:10 , May 18, 2018 |  BC Week In Review  |  Company News

Lilly continues to build cancer pipeline with AurKa acquisition

Eli Lilly and Co. (NYSE:LLY) signed another bolt-on deal to build its cancer pipeline, agreeing on May 14 to buy AurKa Pharma Inc. (Montreal, Quebec) for up to $575 million. The deal came just four...
15:27 , May 14, 2018 |  BC Extra  |  Company News

Lilly continues to build cancer pipeline with AurKa acquisition

Eli Lilly and Co. (NYSE:LLY) signed another bolt-on deal to build its cancer pipeline, agreeing Monday to buy AurKa Pharma Inc. (Montreal, Quebec) for up to $575 million. The deal comes just four days after...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
20:31 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

CASI completes enrollment in Phase II of ENMD-2076 for TNBC

In April, CASI Pharmaceuticals Inc. (NASDAQ:CASI) completed enrollment of 41 patients in a Phase II trial of ENMD-2076 in previously treated patients with locally advanced or metastatic triple-negative breast cancer (TNBC). The open-label, U.S. trial...
19:18 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

CASI reports Phase II data for ENMD-2076 in clear cell ovarian cancer

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, CASI Pharmaceuticals Inc. (NASDAQ:CASI) reported data from 37 evaluable patients with recurrent clear cell ovarian cancer in a Phase II...
22:54 , Jan 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Cell culture and mouse studies suggest dual inhibition of AURKA and JAK-2 could help treat GvHD. In co-cultures of human dendritic cells and allogeneic human T cells, a dual inhibitor of...